Presentation is loading. Please wait.

Presentation is loading. Please wait.

Physician Assessment of Peripheral Neuropathy NCI CTC Grade—Cumulative Dose Source: NDA Addendum. Note: P-value from treatment by dose interaction effect.

Published byNora Lyons Modified over 8 years ago

Similar presentations

Presentation on theme: "Physician Assessment of Peripheral Neuropathy NCI CTC Grade—Cumulative Dose Source: NDA Addendum. Note: P-value from treatment by dose interaction effect."— Presentation transcript:

1 Physician Assessment of Peripheral Neuropathy NCI CTC Grade—Cumulative Dose Source: NDA Addendum. Note: P-value from treatment by dose interaction effect from the following repeated measures model: Y = Treatment Patient (Treatment) Dose Treatment *Dose. Abraxane (N = 229) Taxol (N = 225) P-value = 0.250 NCI CTC Grade NE-7

2 Patient Assessment of Peripheral Neuropathy Total Score by Cumulative Dose Source: NDA Addendum. Note: P-value from treatment by dose interaction effect from the following repeated measures model: Y = Treatment Patient (Treatment) Dose Treatment *Dose. Abraxane (N = 229) Taxol (N = 225) P-value = 0.202 Total Score NE-8

3 Patients with Grade 3 Sensory Neuropathy: Time to Improvement to Grade 1 or 2 (Based on AE Data) Source: NDA Addendum. Note: P-value from log-rank test. Abraxane (N = 24) Taxol (N = 5) Censored P-value = 0.028 Proportion Not Improved NE-9

4 Examples of Drugs Approved as 505(b)(2) NDAs RLD505(b)(2) Product Taxol ® (paclitaxel) Injection (BMS) Abraxane ® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) (Abraxis BioScience, Inc.) Change to an approved drug (different excipient) Genotropin (somatropin for injection) (Pfizer) Omnitrope™ (somatropin [rRNA origin]) for injection (Sandoz, Inc.) Change to an approved drug (follow-on protein/recombinant source) Premarin (conjugated estrogen tablets, USP) (Wyeth) Cenestin tablets (estrogens, conjugated synthetic A) (Duramed) Change to an approved drug (immediate release tablet/synthetic estrogens) RG-2

5 CA008: Summary of Paclitaxel Pharmacokinetic Parameters for Abraxane and Taxol Source: Abraxane NDA PK-3

6 Biodistribution of Abraxane and Taxol Are Similar PK-11

7 Time to Progression Analysis for Phase 3 Study  The following two analyses of TTP have been conducted: 1.TTP based on all on-therapy Investigator response assessments. post-approval commitment, June 2005 2.TTP based on the Independent Radiology Laboratory (IRL) response assessments and Investigator response assessments labeling supplement, July 2006 It makes use of all available response assessments including the IRL assessments for cycles 1–6 and all Investigator assessments, and It uses a conservative approach through cycles 1–6 by selecting the earliest date of progression between the IRL assessments and Investigator assessments These TTP data are currently under review with the FDA TI-1

8 Abraxane Prolonged Time to Tumor Progression CA012: Secondary Endpoint Note: P-value from log-rank test. Abraxane (N = 229) Taxol (N = 224) P-value = 0.002 HR = 0.726 Proportion Not Progressed Abraxane (N = 233) Taxol (N = 227) P-value = 0.002 Hazard Ratio = 0.721 Investigator assessment June 2005 (NDA Post marketing commitment) Time to Tumor Progression Investigator assessment + Independent radiology review July 2006 (Labeling supplement) TI-2

9 Time to Disease Progression Blinded Independent Radiology Laboratory Assessment Source data on file Abraxis BioScience Note: P-value from log-rank test. Abraxane (N = 215) Taxol (N = 214) P-value = 0.003 HR = 0.519 Proportion not Progressed TI-3

Download ppt "Physician Assessment of Peripheral Neuropathy NCI CTC Grade—Cumulative Dose Source: NDA Addendum. Note: P-value from treatment by dose interaction effect."

Similar presentations

NDA 50-772 TLC D-99 Doxorubicin HCL Liposome The Liposome Company, Inc. Proposed Indication: “First line treatment of metastatic breast cancer in combination.

NDA TLC D-99 Doxorubicin HCL Liposome The Liposome Company, Inc. Proposed Indication: “First line treatment of metastatic breast cancer in combination.
Oncologic Drugs Advisory Committee

Oncologic Drugs Advisory Committee
© Frommer Lawrence & Haug LLP BIOSIMILARS: ALTERNATIVE REGULATORY PATHWAYS American Conference Institute FOLLOW-ON BIOLOGICS June 22, 2010 Charles J. Raubicheck.

© Frommer Lawrence & Haug LLP BIOSIMILARS: ALTERNATIVE REGULATORY PATHWAYS American Conference Institute FOLLOW-ON BIOLOGICS June 22, 2010 Charles J. Raubicheck.
Assessment of Adalimumab Dose Selection for Adult Ulcerative Colitis Using Exposure-Response Analyses Michael Bewernitz1, Christine Garnett2,4, Klaus Gottlieb3,

Assessment of Adalimumab Dose Selection for Adult Ulcerative Colitis Using Exposure-Response Analyses Michael Bewernitz1, Christine Garnett2,4, Klaus Gottlieb3,
Robertson JFR et al. J Clin Oncol 2009;27(27):

Robertson JFR et al. J Clin Oncol 2009;27(27):
Pharmaceutical Development and Review Process Rev. 10/21/2014 APGO Interaction with Industry: A Medical Student Guide.

Pharmaceutical Development and Review Process Rev. 10/21/2014 APGO Interaction with Industry: A Medical Student Guide.
+ Drug Development and Review Process. + Objectives Learn the processes involved in drug discovery and development Define the phases involved in FDA drug.

+ Drug Development and Review Process. + Objectives Learn the processes involved in drug discovery and development Define the phases involved in FDA drug.
Meeting Agenda Presentations on endpoints –Regulatory issues –Scientific issues Pros and cons of end points –Classical end points –Non-classical end points.

Meeting Agenda Presentations on endpoints –Regulatory issues –Scientific issues Pros and cons of end points –Classical end points –Non-classical end points.
Oncology Pediatric Initiatives Richard Pazdur, MD Director, Division of Oncology Drug Products.

Oncology Pediatric Initiatives Richard Pazdur, MD Director, Division of Oncology Drug Products.
Presented by Martin H. Cohen, M.D. at the 27 July 2004 meeting of the Oncologic Drugs Advisory Committee.

Presented by Martin H. Cohen, M.D. at the 27 July 2004 meeting of the Oncologic Drugs Advisory Committee.
CR-1 Concluding Remarks and Risk/Benefit Summary Mace L. Rothenberg, MD Professor of Medicine Vanderbilt Ingram Cancer Center.

CR-1 Concluding Remarks and Risk/Benefit Summary Mace L. Rothenberg, MD Professor of Medicine Vanderbilt Ingram Cancer Center.
Entrepreneurship in Biotechnology Columbia University Graduate School of Arts and Sciences BIOT 4180 Columbia University GSAS BIOT 4180.

Entrepreneurship in Biotechnology Columbia University Graduate School of Arts and Sciences BIOT 4180 Columbia University GSAS BIOT 4180.
Approved Products for the Treatment of CMV Retinitis in Immunocompromised Patients William M. Boyd, M.D. Division of Anti-inflammatory, Analgesic, and.

Approved Products for the Treatment of CMV Retinitis in Immunocompromised Patients William M. Boyd, M.D. Division of Anti-inflammatory, Analgesic, and.
Drug Treatment of Metastatic Breast Cancer

Drug Treatment of Metastatic Breast Cancer
Abraxane ® (paclitaxel protein-bound particles for injectable suspension). Each 50 mL vial contains 100 mg of paclitaxel and 900 mg of human albumin.

Abraxane ® (paclitaxel protein-bound particles for injectable suspension). Each 50 mL vial contains 100 mg of paclitaxel and 900 mg of human albumin.
CS-1 Results of the Phase 3 Clinical Trials of Abraxane vs. Taxol in Metastatic Breast Cancer William J. Gradishar, MD, FACP Professor of Medicine Northwestern.

CS-1 Results of the Phase 3 Clinical Trials of Abraxane vs. Taxol in Metastatic Breast Cancer William J. Gradishar, MD, FACP Professor of Medicine Northwestern.
1 March 2003 ODAC: DOXIL ®, Ovarian Cancer ODAC Discussion on Accelerated Approval March 12-13, 2003 DOXIL ® (doxorubicin HCl liposome injection) Treatment.

1 March 2003 ODAC: DOXIL ®, Ovarian Cancer ODAC Discussion on Accelerated Approval March 12-13, 2003 DOXIL ® (doxorubicin HCl liposome injection) Treatment.
A Phase III study (EMBRACE. ) of eribulin mesylate vs

A Phase III study (EMBRACE. ) of eribulin mesylate vs
Phase III study of first-line XELOX plus bevacizumab (BEV) for 6 cycles followed by XELOX plus BEV or single agent (s/a) BEV as maintenance therapy in.

Phase III study of first-line XELOX plus bevacizumab (BEV) for 6 cycles followed by XELOX plus BEV or single agent (s/a) BEV as maintenance therapy in.
ODAC SCHERING-PLOUGH RESEARCH INSTITUTE 1 Temozolomide Oncology Drug Advisory Committee March 13, 2003 Craig L. Tendler, M.D. Vice President, Oncology.

ODAC SCHERING-PLOUGH RESEARCH INSTITUTE 1 Temozolomide Oncology Drug Advisory Committee March 13, 2003 Craig L. Tendler, M.D. Vice President, Oncology.

Similar presentations

Ads by Google